Probiotic Postbiotic Composition for Lung Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for SARS-CoV-2 infection-associated disorders, such as lung inflammation and immune abnormalities, often come with adverse side effects and do not effectively prevent immune system dysregulation.

Innovation Solution

A composition comprising live Bacillus coagulans CB85 and heat-killed Lactobacillus plantarum CB102 is administered to prevent SARS-CoV-2 infection-associated disorders, with the live Bacillus coagulans serving as a probiotic and heat-killed Lactobacillus plantarum as a postbiotic, in a specific ratio of 1:1.47, to alleviate lung inflammation and immune abnormalities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antiviral drugs such as Paxlovid or Remdesivir are used to treat SARS-CoV-2 infection, then the treatment effect is improved, but adverse side effects occur including immune system disruption and organ dysfunction

Engineering Contradiction:

Improvetreatment effectVSAvoidadverse side effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces probiotic bacteria (Lactobacillus plantarum CB102 and Bacillus coagulans CB85) as intermediary substances that mediate the immune response. These probiotics act as a bridge between the host immune system and the viral infection, modulating immune function without directly targeting the virus, thereby avoiding the harmful side effects of conventional antiviral drugs while still providing protective effects against SARS-CoV-2 infection and its complications

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the approach from direct viral inhibition to immune system parameter modulation. By administering probiotics that alter immune system parameters (such as cytokine production, immune cell activation), the body's own defense mechanisms are enhanced to fight the infection, avoiding the toxic effects of pharmacological intervention while maintaining effective treatment

Inventive Principle:

Principle #35Parameter changes

2Object-affected harmful factors

If conventional treatments are used to address lung inflammation and immune abnormalities, then some symptoms are relieved, but immune system dysregulation is not effectively prevented

Engineering Contradiction:

Improvelung inflammationVSAvoidimmune system regulation

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent applies preliminary action by administering probiotics before SARS-CoV-2 infection or at the early stages of infection. The probiotics pre-condition the immune system, establishing a balanced immune state that prevents both excessive inflammation and immune dysregulation. This proactive approach addresses the root cause of immune dysfunction rather than merely treating symptomatic manifestations

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful overactive immune response (cytokine storm) into a beneficial controlled immune response. By using probiotics to modulate the immune system, the excessive inflammatory response is transformed into a balanced, regulated response that effectively fights the virus without causing tissue damage or long-term immune dysregulation

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination significantly improves lung function and reduces the incidence of SARS-CoV-2 infection-associated disorders by modulating the immune response and alleviating lung injury and inflammation, outperforming the use of either component alone.

Implementation Method 1

administering to a subject in need thereof a composition including live Bacillus coagulans CB85 and heat-killed Lactobacillus plantarum CB102

Methodology Applied

Scientific EffectProbiotic effect:

Implementation Method 2

heat-killed Lactobacillus plantarum CB102 is deposited under the Budapest Treaty at the DSMZ GmbH under an accession number DSM 33894

Methodology Applied

Scientific EffectPostbiotic effect:

Data Source

PatentUS20240398878A1Method of using a combination of postbiotics and probiotics for prevention of severe acute respiratory syndrome coronavirus 2 infection-associated disorders

Publication Date: 2024.12.05 CHAMBIO

AI summary

A method for preventing a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-associated disorder includes use of a composition containing live Bacillus coagulans CB85 which is deposited under the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 33893, and heat-killed Lactobacillus plantarum CB102 which is deposited under the Budapest Treaty at the DSMZ GmbH under an accession number DSM 33894.